Paracentesis is the standard treatment for refractory ascites in patients with cirrhosis, but it cannot prevent the recurrence of ascites. The placement of a transjugular intrahepatic portosystemic ...

The frequency and predictors of end-of-life symptom in patients with advanced cancer. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text ...

Large-volume paracentesis is a treatment used to remove excess fluid in the abdominal cavity resulting from such conditions as cirrhosis of the liver or cardiac failure. It is normally performed as an ...

To the Editor: In the article, "Hemodynamics in the Cirrhotic Patient during Paracentesis." which appeared in the March 2 issue of the Journal, Knauer and Lowe report on circulatory changes occurring ...

HERNIA is known to be more frequent among patients with cirrhosis of the liver, especially with ascites, than among those without liver disease. Chapman et al. 1 reported a rate of 10 per cent in 58 ...

W. L. Gore & Associates has reported the enrollment of the first patient in the Gore Early TIPS for Ascites Study at the Indiana University Hospital in Indianapolis. The objective of the study, which ...

J Gastroenterol Hepatol. 2009;24(9):1494-1503. Transjugular Intrahepatic Portosystemic Shunting. Transjugular intrahepatic portosystemic shunting (TIPS) creates an iatrogenic intrahepatic shunt a ...

The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of recurrent or refractory ascites due to cirrhosis, according to a company press release.

Ascites is the most common complication of liver cirrhosis, and it develops as a consequence of portal hypertension and splanchnic vasodilatation. Depending on severity, management of ascites consists ...